Fluoroquinolone preventive therapy for children exposed to MDR-TB

Int J Tuberc Lung Dis. 2022 Feb 1;26(2):171-173. doi: 10.5588/ijtld.21.0443.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / adverse effects
  • Child
  • Fluoroquinolones* / adverse effects
  • Humans
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / prevention & control

Substances

  • Antitubercular Agents
  • Fluoroquinolones